Perceptive Advisors LLC Cuts Stake in Abeona Therapeutics Inc (ABEO)

Perceptive Advisors LLC lowered its stake in shares of Abeona Therapeutics Inc (NASDAQ:ABEO) by 72.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 116,900 shares of the biopharmaceutical company’s stock after selling 305,973 shares during the period. Perceptive Advisors LLC owned about 0.25% of Abeona Therapeutics worth $1,993,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. State of Wisconsin Investment Board acquired a new position in Abeona Therapeutics during the second quarter worth about $122,000. Rhumbline Advisers acquired a new position in Abeona Therapeutics during the second quarter worth about $190,000. Schwab Charles Investment Management Inc. acquired a new position in Abeona Therapeutics during the second quarter worth about $264,000. California State Teachers Retirement System acquired a new position in Abeona Therapeutics during the second quarter worth about $275,000. Finally, Teachers Advisors LLC acquired a new position in Abeona Therapeutics during the second quarter worth about $284,000. 41.95% of the stock is owned by institutional investors and hedge funds.

Abeona Therapeutics Inc (NASDAQ ABEO) opened at $16.20 on Monday. Abeona Therapeutics Inc has a fifty-two week low of $4.05 and a fifty-two week high of $22.75.

Abeona Therapeutics (NASDAQ:ABEO) last posted its earnings results on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.05. The company had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.22 million. Abeona Therapeutics had a negative net margin of 2,946.58% and a negative return on equity of 27.69%. equities research analysts expect that Abeona Therapeutics Inc will post -0.6 earnings per share for the current fiscal year.

A number of equities analysts recently weighed in on ABEO shares. Maxim Group set a $17.00 price target on shares of Abeona Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 16th. Zacks Investment Research lowered shares of Abeona Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 16th. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Abeona Therapeutics in a research report on Thursday, August 24th. Royal Bank Of Canada started coverage on shares of Abeona Therapeutics in a research report on Thursday, September 14th. They set an “outperform” rating and a $23.00 price target on the stock. Finally, Cantor Fitzgerald restated a “buy” rating and set a $21.00 price target on shares of Abeona Therapeutics in a research report on Friday, October 6th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $26.10.

ILLEGAL ACTIVITY WARNING: “Perceptive Advisors LLC Cuts Stake in Abeona Therapeutics Inc (ABEO)” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2017/12/11/perceptive-advisors-llc-cuts-stake-in-abeona-therapeutics-inc-abeo.html.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Institutional Ownership by Quarter for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply